Evidence map›Paper›PMID 37463793›Full record

ArticleLupus2023

Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort.

Trixy David, Li Su, Yafeng Cheng, Caroline Gordon, Benjamin Parker, David Isenberg, John A Reynolds, Ian N Bruce, International Collaborating Clinics Consortium, MASTERPLANS Consortium

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Updates on the Evaluation of Lupus Arthritis.Rheumatology and therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Trixy DavidThe Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Li SuMRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Yafeng ChengMRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Caroline GordonRheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.ORCID 0000-0002-1244-6443
Benjamin ParkerThe Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
David IsenbergCentre for Rheumatology, Division of Medicine, University College London, London, UK.ORCID 0000-0001-9514-2455
John A ReynoldsRheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.ORCID 0000-0002-8962-4404
Ian N BruceThe Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.ORCID 0000-0003-3047-500X
International Collaborating Clinics Consortium
MASTERPLANS Consortium
Manchester Academic Health Science Centre · GBUniversity of Birmingham · GBUniversity of Cambridge · GBUniversity College London · GB

Funding

Medical Research Council MC_UU_00002/15Medical Research Council MR/M01665X/1
6 · The paper itself

Abstract

backgroundWe aimed to identify factors associated with a significant reduction in SLE disease activity over 12 months assessed by the BILAG Index.

methodsIn an international SLE cohort, we studied patients from their 'inception enrolment' visit. We also defined an 'active disease' cohort of patients who had active disease similar to that needed for enrolment into clinical trials. Outcomes at 12 months were; Major Clinical Response (MCR: reduction to classic BILAG C in all domains, steroid dose of ≤7.5 mg and SLEDAI ≤ 4) and 'Improvement' (reduction to ≤1B score in previously active organs; no new BILAG A/B; stable or reduced steroid dose; no increase in SLEDAI). Univariate and multivariate logistic regression with Least Absolute Shrinkage and Selection Operator (LASSO) and cross-validation in randomly split samples were used to build prediction models.

results'Inception enrolment' (

conclusionBaseline predictors of response in SLE can help identify patients in clinic who are less likely to respond to standard therapy. They are also important as stratification factors when designing clinical trials in order to better standardize overall usual care response rates.

Indexed as

Lupus Erythematosus, SystemicHumansImmunosuppressive AgentsLogistic ModelsOutcome Assessment, Health CareSeverity of Illness IndexUnited KingdomImmunosuppressive Agentsclinical outcomesdisease activitypredictorsSystemic lupus erythematosus

Identifiers

PMID37463793
PMCPMC7614893
OpenAlexW4384659337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.